


RHEUMATOID ARTHRITIS



References:

1. Multiple sclerosis: Current treatment algorithms; Article in Current opinion in neurology · June 2011 .
2. 2015 American College of Rheumatology Guideline for the Treatment of Rheumatoid Arthritis; Arthritis Care & Research DOI 10.1002/acr.22783 VC 2015, American College of Rheumatology.

SPECIALTY DRUGS

QUICK REFERENCE GUIDE Part I

Rheumatoid Arthritis and Multiple Sclerosis



DEPARTAMENTO DE FARMACIA
PO Box 364988
San Juan, P.R. 00936-4988

Centro de Servicio de Farmacia
1-888-558-5501

Unidad de Preautorizaciones
1-844-606-7171

DRUG THERAPEUTIC CLASS

PDL	PDL LOW COST ALTERNATIVE*	MONTHLY AVG. COST/ 30 DAYS SUPPLY
IMMUNOMODULATORS (TNF and Non-TNF) FOR RHEUMATOID ARTHRITIS		
Subcutaneous (SQ) Agents		
Enbrel		\$ 4,917.31
	Cimzia	Initial dose: \$ 12,636.54 Maintenance dose: \$ 4,237.78
Humira+ MTX		\$ 5,042.37
Humira		\$ 9,892.72
IV Agents		
Orencia		Initial dose: \$10,119.51 Maintenance dose: \$ 3,372.57
Remicade		Induction dose: \$ 5,318.36 Maintenance dose: \$ 2,619.56– 9,055.13
IV + SQ Agent		
	Orencia	Initial dose: \$7,773.14 Maintenance dose: \$4,360.57
MULTIPLE SCLEROSIS AGENTS		
	Ampyra	\$ 2,018.24
	Copaxone	\$ 5,644.80
	Tysabri	\$ 5,831.79
	Avonex	\$ 6,130.97
Tecfidera		\$ 6,467.03
Betaseron		\$ 6,498.13
Gilenya		\$ 6,978.20
GROWTH HORMONES ANALOGS		
	Norditropin	\$ 4,834.73
ANTIHEMOPHILIC TYPE A		
	Hemofil M	\$ 1.60 per unit**
	Rixubis	\$ 1.75 per unit**
Advate		\$ 1.82 per unit**
Recombinate		\$ 1.82 per unit**
Electate		\$ 2.47 per unit**
ERYTHROPOEISIS STIMULATING AGENTS		
	Aranesp	\$ 1,574.91
Procrit		\$ 3,412.95

DRUG THERAPEUTIC CLASS

PDL	PDL LOW COST ALTERNATIVE	MONTHLY AVG. COST/ 30 DAYS SUPPLY
COLONY STIMULATING FACTORS		
	Neupogen	\$ 2,683.93
Neulasta		\$ 6,834.75
CHEMOTHERAPIES		
Antineoplastic Enzyme Inhibitors		
imatinib		\$ 7,804.57
Sprycel		\$ 10,720.81
Tasigna		\$ 11,166.33
Afinitor		\$ 12,666.60
Nexavar		\$ 16,037.16
Aromatase Inhibitors		
	anastrozole	\$ 5.41
	letrozole	\$ 5.18
Antiandrogens		
	bicalutamide	\$ 10.68
	flutamide	\$ 45.00
Antiestrogen		
	tamoxifen	\$ 16.83
Luteinizing Hormone Releasing Analog		
Lupron Depot		\$ 3,808.60
Alkylating Agents		
	lomustine	\$ 416.52
	Alkeran	\$ 450.00
temozolamide		\$ 1,391.20
Leukeran		\$ 5,290.32
Myleran		\$ 1,200.00
Antimetabolites		
	hydroxyurea	\$ 20.73
	methotrexate	\$ 29.20
	mercaptopurine	\$ 34.02
capecitabine		\$ 1,424.02
Folic Acid Antagonists Rescue Agents		
Leucovorin calcium		\$ 171.03
PULMONARY HYPERTENSION AGENTS		
	sildenafil	\$ 43.77
Adempas		\$ 9,270.04


*Medications in red are more cost effective .

** Cost are per unit. Not the monthly average cost.

* Weight-based dosing.

MULTIPLE SCLEROSIS

Current algorithm for the management of clinically isolated syndrome at risk and active relapsing–remitting multiple sclerosis ¹



In the case of suboptimal response or intolerance to first-line therapies: (a) consider switching among first-line therapies;
 (b) consider second-line therapies. In the case of sub-optimal response or intolerance to second line therapies:
 (c) consider changing to third-line therapies.

¹Fingolimod is approved in the USA as first line. CIS, clinically isolated syndrome; GA, glatiramer acetate; IFNb, interferon-beta; MS, multiple sclerosis.